This is a promotional website intended for licensed healthcare professionals or prescribed patients in the United Kingdom or Republic of Ireland. Please select one of the following:
The pooled clinical safety database for Voraxaze® includes data for 232 patients up to 17 years of age1
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Abbreviations: CIR, clinically important reduction;HPLC, high-performance liquid chromatography; MTX, methotrexate.
References
Summary of Product Characteristics (SmPC)®.
UK-VRX-2600033 Date of Last Revision: February 2026
United States
Germany
United Kingdom